Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 1998

View Archived Issues

Disappointing results of pilot study of SDZ-PSC-833 + doxorubicin in colorectal cancer

More data reported for ADCON-P; FDA okays pivotal trial

Aphton initiates phase I/II trial of Gonadimmune in prostate cancer patients

Hybridon advances antisense drug to phase II

Another market introduction for Novartis bisphosphonate

Introgen acquires option to license Bak gene from LXR

Cortecs: year-end 1998 highlights

COHERE will track long-term effects of beta-blockade in heart failure

Nobel award brings nitric oxide into the limelight

Novel series of inhibitors of protein farnesyltransferase developed at RPR

New heteroarylsulfonamide derivatives from Knoll with broad clinical application

Stroke patients benefit from treatment with anti-ICAM-1 MAb

Bicyclic inhibitors of protein farnesyltransferase for cancer, restenosis, etc.

Roche presents series of OFQ (ORL1) receptor agonists/antagonists

Immunomodulating thalidomide analogues patented by Gruenenthal

Genset, Pharmacia & Upjohn collaborate in pharmacogenomics research

Abbott will collaborate with Nippon Shinyaku on development of incontinence Rx

U.S. patent covers protegrins and synthetic analogues such as IntraBiotics' IB-367

Fluoroquinolone derivative K-12 inhibits HIV in vitro

Demegen receives patent protection for Peptidyl MIMs in cancer indications

Antibody-based cancer product from AltaRex heading for phase I testing

Access signs more agreements for distribution of amlexanox

Successful completion of human safety trials reported for VIMRx wound-healing agent

AHP and Monsanto agree not to merge

Asahi expects approval of dysuria Rx in near future

CEA-Cide receives orphan drug designation

Treatment recommendations for generalized convulsive status epilepticus emerge from VA study

Rituximab now available in Germany

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...